Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) doses the final three patients under cohort three of the Phase I intravenous (IV) clinical trial of RECCE327 (R327)
- The study is evaluating the safety and pharmacokinetics of R327 in seven to 10 subjects with doses ranging from 50 to 16,000 milligrams
- The three new patients received 500 milligrams of R327, with all 10 patients dosed so far indicating a good safety and tolerability profile
- Recruitment for the fourth cohort is underway and the study remains on track to have all phase I dosing completed by Q2 2022
- Recce finished the day up 1.84 per cent to $1.11
Recce Pharmaceuticals (RCE) has dosed the final three patients of cohort three under the Phase I intravenous (IV) clinical trial of RECCE327 (R327).
The phase I trial is an increasing dose, randomised, placebo-controlled, parallel, double-blind, single-dose study being undertaken at Adelaide’s CMAX clinical trial facility.
The study is evaluating the safety and pharmacokinetics of R327 in seven to 10 subjects with doses ranging from 50 to 16,000 milligrams.
R327 is an intravenous (in vein) therapy that is being developed for the treatment against serious and life-threatening infections.
According to PEW Charitable Trusts global antibiotics pipeline review, it is the only clinical-stage new class of antibiotic in the world being developed for sepsis.
The three new patients received 500 milligrams of R327, with all 10 patients dosed so far indicating a good safety and tolerability profile.
Recruitment for the fourth cohort is underway and the study remains on track to have all phase I dosing completed by Q2 2022.
“Completing this cohort with the maximum number of subjects, sees R327 further a compelling safety profile at a milestone dose,” CEO James Graham stated.
“We anticipate recommendation to start dosing cohort four at higher concentrations again in the near weeks.”
Recce finished the day up 1.84 per cent to $1.11.
